Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 6.44
SSH's Cash to Debt is ranked higher than
59% of the 311 Companies
in the Global Medical Devices industry.

( Industry Median: 2.27 vs. SSH: 6.44 )
Ranked among companies with meaningful Cash to Debt only.
SSH' s 10-Year Cash to Debt Range
Min: 6.44   Max: No Debt
Current: 6.44

Equity to Asset 0.78
SSH's Equity to Asset is ranked higher than
71% of the 282 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. SSH: 0.78 )
Ranked among companies with meaningful Equity to Asset only.
SSH' s 10-Year Equity to Asset Range
Min: 0.78   Max: 0.95
Current: 0.78

0.78
0.95
Interest Coverage No Debt
SSH's Interest Coverage is ranked higher than
86% of the 161 Companies
in the Global Medical Devices industry.

( Industry Median: 10000.00 vs. SSH: No Debt )
Ranked among companies with meaningful Interest Coverage only.
SSH' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 2
Z-Score: -0.63
M-Score: -99999999.99
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -8953.90
SSH's Operating margin (%) is ranked lower than
98% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 3.51 vs. SSH: -8953.90 )
Ranked among companies with meaningful Operating margin (%) only.
SSH' s 10-Year Operating margin (%) Range
Min: -38764.41   Max: -358.24
Current: -8953.9

-38764.41
-358.24
Net-margin (%) -8921.36
SSH's Net-margin (%) is ranked lower than
98% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 1.99 vs. SSH: -8921.36 )
Ranked among companies with meaningful Net-margin (%) only.
SSH' s 10-Year Net-margin (%) Range
Min: -36877.97   Max: -358.24
Current: -8921.36

-36877.97
-358.24
ROE (%) -72.67
SSH's ROE (%) is ranked lower than
86% of the 285 Companies
in the Global Medical Devices industry.

( Industry Median: 3.24 vs. SSH: -72.67 )
Ranked among companies with meaningful ROE (%) only.
SSH' s 10-Year ROE (%) Range
Min: -238.68   Max: -63.22
Current: -72.67

-238.68
-63.22
ROA (%) -65.40
SSH's ROA (%) is ranked lower than
85% of the 313 Companies
in the Global Medical Devices industry.

( Industry Median: -0.11 vs. SSH: -65.40 )
Ranked among companies with meaningful ROA (%) only.
SSH' s 10-Year ROA (%) Range
Min: -216.94   Max: -58.42
Current: -65.4

-216.94
-58.42
ROC (Joel Greenblatt) (%) -4327.33
SSH's ROC (Joel Greenblatt) (%) is ranked lower than
93% of the 308 Companies
in the Global Medical Devices industry.

( Industry Median: 3.35 vs. SSH: -4327.33 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
SSH' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -4851.22   Max: -774.91
Current: -4327.33

-4851.22
-774.91
EBITDA Growth (3Y)(%) 432.50
SSH's EBITDA Growth (3Y)(%) is ranked higher than
99% of the 155 Companies
in the Global Medical Devices industry.

( Industry Median: 0.90 vs. SSH: 432.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
SSH' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 462.5
Current: 432.5

0
462.5
EPS Growth (3Y)(%) 322.70
SSH's EPS Growth (3Y)(%) is ranked higher than
98% of the 160 Companies
in the Global Medical Devices industry.

( Industry Median: -4.90 vs. SSH: 322.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
SSH' s 10-Year EPS Growth (3Y)(%) Range
Min: 0   Max: 455
Current: 322.7

0
455
» SSH's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

SSH Guru Trades in

SSH Guru Trades in

Q3 2013

SSH Guru Trades in Q3 2013

Jim Simons 17,000 sh (New)
» More
Q4 2013

SSH Guru Trades in Q4 2013

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with SSH

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.60
SSH's P/B is ranked higher than
50% of the 269 Companies
in the Global Medical Devices industry.

( Industry Median: 2.55 vs. SSH: 2.60 )
Ranked among companies with meaningful P/B only.
SSH' s 10-Year P/B Range
Min: 2.1   Max: 3.32
Current: 2.6

2.1
3.32
P/S 241.70
SSH's P/S is ranked lower than
144% of the 266 Companies
in the Global Medical Devices industry.

( Industry Median: 2.18 vs. SSH: 241.70 )
Ranked among companies with meaningful P/S only.
SSH' s 10-Year P/S Range
Min: 241.7   Max: 575
Current: 241.7

241.7
575
Current Ratio 10.33
SSH's Current Ratio is ranked higher than
94% of the 308 Companies
in the Global Medical Devices industry.

( Industry Median: 2.48 vs. SSH: 10.33 )
Ranked among companies with meaningful Current Ratio only.
SSH' s 10-Year Current Ratio Range
Min: 1.06   Max: 63.13
Current: 10.33

1.06
63.13
Quick Ratio 10.33
SSH's Quick Ratio is ranked higher than
94% of the 308 Companies
in the Global Medical Devices industry.

( Industry Median: 1.95 vs. SSH: 10.33 )
Ranked among companies with meaningful Quick Ratio only.
SSH' s 10-Year Quick Ratio Range
Min: 1.06   Max: 63.13
Current: 10.33

1.06
63.13
Days Sales Outstanding 73.00
SSH's Days Sales Outstanding is ranked lower than
55% of the 267 Companies
in the Global Medical Devices industry.

( Industry Median: 67.63 vs. SSH: 73.00 )
Ranked among companies with meaningful Days Sales Outstanding only.
SSH' s 10-Year Days Sales Outstanding Range
Min: 6.99   Max: 803
Current: 73

6.99
803

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.70
SSH's Price/Net Cash is ranked higher than
94% of the 110 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. SSH: 2.70 )
Ranked among companies with meaningful Price/Net Cash only.
SSH' s 10-Year Price/Net Cash Range
Min: 2.2   Max: 31.61
Current: 2.7

2.2
31.61
Price/Net Current Asset Value 2.70
SSH's Price/Net Current Asset Value is ranked higher than
94% of the 157 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. SSH: 2.70 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
SSH' s 10-Year Price/Net Current Asset Value Range
Min: 2.16   Max: 163
Current: 2.7

2.16
163
Price/Tangible Book 2.50
SSH's Price/Tangible Book is ranked higher than
74% of the 249 Companies
in the Global Medical Devices industry.

( Industry Median: 3.10 vs. SSH: 2.50 )
Ranked among companies with meaningful Price/Tangible Book only.
SSH' s 10-Year Price/Tangible Book Range
Min: 2.13   Max: 32.6
Current: 2.5

2.13
32.6
Price/Median PS Value 1.00
SSH's Price/Median PS Value is ranked higher than
65% of the 269 Companies
in the Global Medical Devices industry.

( Industry Median: 1.00 vs. SSH: 1.00 )
Ranked among companies with meaningful Price/Median PS Value only.
SSH' s 10-Year Price/Median PS Value Range
Min: 0.99   Max: 0.99
Current: 1

Earnings Yield (Greenblatt) -57.50
SSH's Earnings Yield (Greenblatt) is ranked lower than
105% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 1.10 vs. SSH: -57.50 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
SSH' s 10-Year Earnings Yield (Greenblatt) Range
Min: -1413.4   Max: 0
Current: -57.5

-1413.4
0

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:SHC.Australia, 22S.Germany,
Sunshine Heart Inc was incorporated in Delaware on August 22, 2002. The company is an early-stage medical device company engaged in developing, manufacturing and commercializing its C-Pulse Heart Assist System for treatment of Class III and ambulatory Class IV heart failure. Its C-Pulse Heart Assist System utilizes the scientific principles of intra-aortic balloon counter-pulsation applied in an extra-aortic approach to assist the left ventricle by reducing the workload required to pump blood throughout the body, while increasing blood flow to the coronary arteries. It is in the process of obtaining regulatory approvals necessary to sell its product. Combined, these potential benefits may help reverse the heart failure process or maintain the patient's current condition, thereby potentially preventing the need for later-stage heart failure devices, such as LVADs, artificial hearts or transplants. Its competitors include: AbioMed, Inc., Berlin Heart GmbH, CardioKinetix, Inc., CircuLite, Inc. & HeartWare International Inc. Its business is subject to extensive federal and state government regulation.
» More Articles for NAS:SSH

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
SUNSHINE HEART, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Other... May 26 2015
Sunshine Heart Announces FDA Approval to Resume Enrollment in COUNTER HF(TM) US Pivotal Study for... May 26 2015
5:33 am Sunshine Heart receives FDA approval to resume COUNTER HF pivotal study enrollment May 26 2015
Sunshine Heart Announces FDA Approval to Resume Enrollment in COUNTER HF(TM) US Pivotal Study for... May 26 2015
SUNSHINE HEART, INC. Financials May 20 2015
10-Q for Sunshine Heart, Inc. May 10 2015
SUNSHINE HEART, INC. Files SEC form 10-Q, Quarterly Report May 07 2015
Q1 2015 Sunshine Heart Inc Earnings Release - Before Market Open May 05 2015
Sunshine Heart Announces First Quarter 2015 Results and Provides Corporate Update May 05 2015
SUNSHINE HEART, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... May 05 2015
Sunshine Heart Announces First Quarter 2015 Results and Provides Corporate Update May 05 2015
10-K for Sunshine Heart, Inc. May 02 2015
Sunshine Heart to Release First Quarter 2015 Results on May 5, 2015 Apr 28 2015
Sunshine Heart to Release First Quarter 2015 Results on May 5, 2015 Apr 28 2015
SUNSHINE HEART, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... Apr 23 2015
Sunshine Heart Provides Update on U.S. Pivotal Study of C-Pulse(R) Heart Assist System Apr 18 2015
SUNSHINE HEART, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Apr 17 2015
Excitement Among Proof-of-Concept Drug Companies Could Spill Over Into This Lesser-Known Name Apr 17 2015
Sunshine Heart Provides Update on U.S. Pivotal Study of C-Pulse(R) Heart Assist System Apr 16 2015
SUNSHINE HEART, INC. Files SEC form 10-K, Annual Report Mar 20 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK